KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
about
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring.Possible application of circulating free tumor DNA in non-small cell lung cancer patients.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
P2860
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@ast
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@en
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@nl
type
label
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@ast
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@en
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@nl
prefLabel
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@ast
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@en
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@nl
P2093
P2860
P356
P1476
KRAS mutations in the circulat ...... l lung cancer (NSCLC) patients
@en
P2093
Alejandro Martínez
Clara Mayo
Cristina Teixidó
Daniela Morales-Espinosa
Maria de los Llanos Gil
Mónica Garzón
Rafael Rosell
Santiago Viteri
Sergi Villatoro
P2860
P304
P356
10.21037/TLCR.2016.10.14
P407
P577
2016-10-01T00:00:00Z